- Home
- STSS vs LITS Comparison
STSS vs LITS Comparison
Compare STSS & LITS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STSS | LITS |
|---|---|---|
| Founded | 2017 | 2000 |
| Country | United States | United States |
| Employees | 55 | 4 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 44.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | STSS | LITS |
|---|---|---|
| Price | $1.84 | $1.08 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 246.3K | ★ 340.3K |
| Earning Date | 04-06-2026 | 05-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.42 | $0.95 |
| 52 Week High | $18.23 | $3.03 |
Technical Indicators
Market Signals| Indicator | STSS | LITS |
|---|---|---|
| Relative Strength Index (RSI) | 47.21 | 40.15 |
| Support Level | $1.66 | $0.98 |
| Resistance Level | $2.00 | $1.25 |
| Average True Range (ATR) | 0.10 | 0.06 |
| MACD | -0.02 | -0.01 |
| Stochastic Oscillator | 18.75 | 0.00 |
Price Performance
Historical ComparisonAbout STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device and pharmaceutical packaging company offering patented, smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities that incorporate syringe technologies that use both passive and active safety features. The Company has adopted a digital asset treasury scheme focused on accumulating SOL, the native digital asset of the Solana blockchain, leveraging capital markets raises to power on-chain yield generation with the Solana Ecosystem.
About LITS Lite Strategy Inc.
Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.